TY - JOUR T1 - Enhancement of Radiation Response Associated With Metformin in Hepatocellular Carcinoma: Preclinical Animal and Clinical Cohort Study JF - Anticancer Research JO - Anticancer Res SP - 867 LP - 876 DO - 10.21873/anticanres.15544 VL - 42 IS - 2 AU - WON IL JANG AU - MI-SOOK KIM AU - JAE-HOON JEONG AU - WONWOO KIM AU - JAE SUNG KIM Y1 - 2022/02/01 UR - http://ar.iiarjournals.org/content/42/2/867.abstract N2 - Background/Aim: This study examined whether metformin can enhance the radiation response in a hepatocellular carcinoma (HCC) xenograft mice model and patient population. Materials and Methods: Huh-7 human HCC-bearing xenograft mice were treated with gamma-ray, metformin, neutron therapy, and their combinations. Tumour growth and lung colonies were assessed. Overall, 145 patients who underwent radiotherapy for HCC were retrospectively analysed. Results: The combinations of gamma-ray and metformin and neutron radiation and metformin inhibited tumour growth and metastatic lung nodule formation when compared to the monotherapy and gamma-ray groups, respectively. In patients who received radiotherapy for HCC, the overall survival rate was higher in the metformin-treated group than in the non-metformin group. Conclusion: Metformin inhibited tumour growth and metastasis in HCC by enhancing the radiation response in animal experiments. Additionally, metformin was also found to be associated with a higher survival outcome in patients with HCC. ER -